Eravacycline Dihydrochloride

盐酸依拉环素

Report date: 2026/03/19 20:00:18
NMEQIDP

Base Information

Drug NameEravacycline Dihydrochloride
Drug Alias Nameeravaciclina依拉环素依雷环素Eravacycline hydrochloride依拉环素盐酸盐 +[10] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Tetracycline antibiotics
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsCommunity-acquired bacterial pneumoniaNeutropeniaKidney Failure, Chronic +[9] 
Global Approved IndicationsIntraabdominal InfectionsBacterial Infections
Approved Indications in ChinaIntraabdominal Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/27
Country/TerritoryCzechiaBulgariaUnited States +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTetraphase Pharmaceuticals IncParatek Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesYunding Xinyao Co LtdPAION Pharma GmbHEverest Medicines Ltd +[7] 
Inactive CompaniesEverest Medicines (Us) Ltd
Active IndicationsNeutropeniaHematologic NeoplasmsIntraabdominal Infections +[4] 
Inactive IndicationsCommunity-acquired bacterial pneumoniaKidney Failure, ChronicHepatic Insufficiency +[5] 

Other Information

ATC CodeJ01AA
Related LinksWikipediaDrugBankKEGG